This designation applies to adult patients with recurrent or refractory multiple myeloma (RRMM) who have been administered at least three previous therapeutic strains, including proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies.
ISB 2001 is a TRI-specific antibody therapeutic designed to target BCMA and CD38 in myeloma cells, and CD3 on T cells, allowing targeted immune responses against cancer. This treatment is currently being evaluated in a Phase 1 Dose Distension Clinical Study.
Ichnos Glenmark Innovation recently completed the dose escalation portion of a phase 1 clinical trial in patients with pre-treated multiple myeloma.
The first results of the study presented during the oral session at the American Society of Hematology (ASH) Annual Meeting in December 2024 showed overall overall response rate (ORR), durable responses, and a favorable safety profile.
The rapid oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 2, 2025 will present the full results of the dose escalation portion. The FDA’s fast track designation aims to accelerate reviews of drugs intended to promote development, treat serious conditions, and treat serious conditions frequently through patients, to achieve the goals of patients’ frequent fast forment emplage emplage emplage emplage emplage emplage emplage compration, and to accelerate reviews of drugs intended to treat serious conditions and treat them frequently and frequently through patients. Conferences and communications with the FDA, as well as rolling reviews of marketing applications.
Additionally, if certain criteria are met, they are eligible for priority review. In particular, ISB 2001 was previously given the “orphan drug” designation by the FDA in July 2023.
Read again:8 nifty micro cap stocks that can jump 100-230% in the next 12 months
Glenmark Pharma: Price Target
According to Trendlyne’s data, the average target price for the stock is Rs 1,691, indicating a 20% increase from the current level. The consensus recommendation from 12 analysts is “purchase.”
Read again: 5 Timeless Warren Buffett cites quotes that all investors should know
Glenmark Pharma: Stock Price Performance
On Monday, Glenmark’s Pharma shares rose 2.2% at BSE’s Rs 1,405.7, while benchmark Sensex rose 0.37%. Stocks have fallen 13% since the start of the year, but have skyrocketed 155% over the past two years. The current market capitalization is Rs 39,670.
Read again: SBI, LICs out of 10 large caps below industry PE levels can collect up to 32%
(Disclaimer: The recommendations, suggestions, opinions and opinions given by experts are their own. (These do not represent views of the economic era)
